Bavarian Nordic Announces First Half 2015 Results
August 25, 2015 01:01 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark, August 25, 2015 -...
Bavarian Nordic to Host First Half 2015 Results Conference Call
August 19, 2015 11:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark - August 19, 2015 - Bavarian...
Bavarian Nordic afholder telefonkonference i forbindelse med offentliggørelsen af regnskabet for første halvår 2015
August 19, 2015 11:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, 19. august 2015 - Bavarian Nordic A/S...
Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN(r) in Respiratory Syncitial Virus (RSV)
August 18, 2015 10:09 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, Aug. 18, 2015 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of a Phase 1 clinical study of its MVA-BN® RSV vaccine candidate...
Bavarian Nordic påbegynder fase 1 forsøg med MVA-BN® i respiratorisk syncytial virus (RSV)
August 18, 2015 10:03 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, Danmark - 18. august 2015 - Bavarian...
Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN® in Respiratory Syncitial Virus (RSV)
August 18, 2015 10:03 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark - August 18, 2015 - Bavarian...
James B. Breitmeyer fratræder som EVP og Chief Development Officer i Bavarian Nordic
August 05, 2015 02:00 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, Danmark - 5. august 2015 -...
Bavarian Nordic Announces the Resignation of James B. Breitmeyer as EVP and Chief Development Officer
August 05, 2015 02:00 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark - August 5, 2015 -...
Bavarian Nordic Announces Initiation of NCI-sponsored Phase 2 Study of PROSTVAC in Patients with Localized Prostate Cancer
July 24, 2015 01:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Multi-center, placebo-controlled study designed...
Bavarian Nordic offentliggør påbegyndelse af NCI-sponsoreret fase 2 forsøg med PROSTVAC i patienter med lokaliseret prostatacancer
July 24, 2015 01:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Multicenter, placebokontrolleret forsøg vil...